The contribution of NKT cells, NK cells, and other γ-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors

Journal of Immunology

Volumn 170, Issue 3, 2003, Pages 1197-1201

  Park, Se Ho ^a,b   Kyin, Tim ^a   Bendelac, Albert ^a,d   Carnaud, Claude ^a,c  

^a PRINCETON UNIVERSITY   (United States)

^b Korea University   (South Korea)

^c INSERM   (France)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; LIVER METASTASIS; LYMPHOID CELL; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; T LYMPHOCYTE; TUMOR REJECTION;

EID: 0037307796     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.3.1197     Document Type: Article

References (24)

1. Park, S. H., and A. Bendelac. 2000. CD1-restricted T-cell responses and microbial infection. Nature 406:788.
2. Hong, S., D. C. Scherer, N. Singh, S. K. Mendiratta, I. Serizawa, Y. Koezuka, and L. Van Kaer. 1999. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol. Rev. 169:31.
3. Carnaud, C., D. Lee, O. Donnars, S.-H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:4647.
4. Eberl, G., and H. R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30:985.
5. Colombo, M. P., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13:155.
6. Cui, J., T. Shin, T. Kawano, H. Sato, E. Kondo, I. Toura, Y. Kaneko, H. Koseki, M. Kanno, and M. Taniguchi. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623.
7. Kodama, T., K. Takeda, O. Shimozato, Y. Hayakawa, M. Atsuta, K. Kobayashi, M. Ito, H. Yagita, and K. Okumura. 1999. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur. J. Immunol. 29:1390.
8. Smyth, M. J., K. Y. Thia, S. E. Street, E. Cretney, J. A. Trapani, M. Taniguchi, T. Kawano, S. B. Pelikan, N. Y. Crowe, and D. I. Godfrey. 2000. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191:661.
9. Fehniger, T. A., H. Yu, M. A. Cooper, K. Suzuki, M. H. Shah, and M. A. Caligiuri. 2000. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-γ production in vivo. J. Immunol. 164:1643.
10. Kim, S., K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 97:2731.
11. Dieli, F., G. Sireci, D. Russo, M. Taniguchi, J. Ivanyi, C. Fernandez, M. Troye-Blomberg, G. De Leo, and A. Salerno. 2000. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J. Exp. Med. 192:1645.
12. Smyth, M. J., and D. I. Godfrey. 2001. NKT cells and tumor immunity: a double edged sword. Nat. Immun. 1:459.
13. Park, S. H., D. Guy-Grand, F. A. Lemonnier, C. R. Wang, A. Bendelac, and B. Jabri. 1999. Selection and expansion of CD8α/α(1) T cell receptor α/β(1) intestinal intraepithelial lymphocytes in the absence of both classical major histocompatibility complex class I and nonclassical CD1 molecules. J. Exp. Med. 190:885.
14. Benlagha, K., T. Kyin, A. Beavis, L. Teyton, and A. Bendelac. 2002. A thymic precursor to the NKT cell lineage. Science 296:553.
15. Eberl, G., and H. R. MacDonald. 1998. Rapid death and regeneration of NKT cells in anti-CD3ε- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity. 9:345.
16. Pardoll, D. M. 1993. Cancer vaccines. Immunol. Today 14:310.
17. Medzhitov, R., and C. A. Janeway, Jr. 1998. Innate immune recognition and control of adaptive immune responses. Semin. Immunol. 10:351.
18. Boehm, U., T. Klamp, M. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749.
19. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121.
20. Crowe, N. Y., M. J. Smyth, and D. I. Godfrey. 2002. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J. Exp. Med. 196:119.
21. + T cells in IL-12-induced immune responses in vivo. J. Immunol. 160:16.
22. + lymphoid dendritic cells. J. Exp. Med. 189:1981.
23. Emoto, M., M. Miyamoto, I. Yoshizawa, Y. Emoto, U. E. Schaible, E. Kita, and S. H. E. Kaufmann. 2002. Critical role of NK cells rather than Va14 NKT cells in LPS-induced lethal shock in mice. J. Immunol. 169:1426.
24. Karnbach, C., M. R. Daws, E. C. Niemi, and M. C. Nakamura. 2001. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population. J. Immunol. 167:2569.